WASHINGTON - Viagra and other impotence drugs are about to bear new warnings that users may tadalafil cialis sudden hearing loss. Cheap tadalafil It’s not clear that the drugs truly trigger hearing loss, but the Food and Drug Administration decided Thursday to add a warning about the possible risk after counting 29 reports of the problem since 1996 among users of this family of medicines. The impotence drugs Viagra, Cialis and Levitra will bear the warnings. So will Revatio, a drug for pulmonary hypertension, which contains the same dosage tadalafil as Viagra. Viagra’s label already tadalafil experience hearing loss as a possibility, because a few cases were reported during initial testing of that drug. But given that hearing loss is a risk of terapia tadalafil age and certain conditions, such as diabetes and heart disease, that can lead to impotence, it wasn’t clear if the link was real. That still isn’t clear, said FDA ear nose and throat specialist Dr. Robert Boucher. But in poring over FDA’s database of possible drug reactions, what struck him was these 29 reports said the hearing loss occurred without hours to two days of taking one of the drugs. “We don’t know enough to say that it’s ironclad caused by the drugs, but we see enough to say we can’t ignore it either,” he said. The reports involve hearing loss in one ear, which in a third of cases was temporary. FDA urged patients who experience any hearing problems — loss or ringing in the ears — to promptly call their doctors and stop taking the impotence drugs.

CHICAGO (Reuters) -
Eli Lilly & Co (LLY.N) said on Friday
that it had won approval to market its blockbuster osteoporosis
drug to post-menopausal women who are at high risk for invasive
breast cancer.

The company also said U.S. health regulators had extended
the use of the drug, known as Evista, to help reduce the risk
of the aggressive form of breast cancer in post-menopausal
women who have the bone-thinning disease.

However, the drug will also contain a stronger warning of
side effects that can include death by stroke.

Evista, known generically as raloxifene, is already
approved for the prevention and treatment of osteoporosis, or
bone thinning, in post-menopausal women.

Lilly said Evista, like the hormone estrogen, helps to
fight osteoporosis. But Evista also blocks estrogen in breast
tissue, the drug maker said.

Sales of Evista, a selective estrogen receptor modulator,
topped $1 billion in 2006.

SERMs are drugs used to treat osteoporosis that also appear
to prevent breast cancer by reducing estrogen in breast tissue.
Estrogen in breast tissue can drive some types of breast
cancer.

“This data's been unfolding for the last few years, so it's
not as if physicians are not aware of this, but now Lilly will
be able to market it,” said Deutsche Bank analyst Barbara Ryan.

In 2007, Evista sales were flat with the prior year, she
noted. “Our view is that this (approval) may begin to deliver
some growth of maybe 10 to 20 percent,” she said.

That would equate to roughly $100 million to $200 million
in incremental revenues annually. “But it doesn't terapia tadalafil

move the needle at Lilly,” Ryan said. “So it's not momentous,
but we'll watch the scripts like everyone else, and maybe we'll
be surprised.”

Lilly, whose other products include antidepressant Prozac
and erectile dysfunction drug Cialis, reported second-quarter
revenue of $4.63 billion.

Earlier this year, Lilly updated the label for Evista to
include safety information from a clinical trial that evaluated
post-menopausal women, some of whom were suffering from
coronary artery disease and some who were at increased risk for
coronary disease.

The trial found no increase in the incidence of stroke but
an increase in the incidence of death because of stroke.

Since the new label for Evista will include new uses and an
expanded patient population, Lilly has worked with the FDA to
revise the package insert. The insert will now emphasize that
women with an active or past history of venous cialis tadalafil generic rezeptfrei

– potentially deadly blood clots — should not take Evista and
that women at risk for stroke should receive the drug only
after careful evaluation.

A company tadalafil pills
said the so-called black-box warning
did not preclude the company from conducting direct-to-consumer
advertising.

The company presented studies of 37,000 women that compared
Evista with a placebo or tamoxifen, which has been used about
25 years to treat patients with advanced breast cancer.

Competing osteoporosis drugs include Merck & Co Inc's
(MRK.N) Fosamax, and Roche Holding AG's (ROG.VX) and
GlaxoSmithKline Plc's (GSK.L) Boniva.

Shares of Eli Lilly were down 33 cents at $56.85 in morning
New York Stock Exchange trade. Their price has ranged from
$51.13 to $60.63 during the past 52 weeks.

(Reporting by Debra Sherman)

INDIANAPOLIS - Core medicines Zyprexa and Cymbalta helped Eli Lilly and Co. beat Wall Street’s cialis online free sample
cialis western open
, although profits fell 19 percent at the cialis comprar generic
company because of acquisition costs.

The drug maker’s earnings fell to $663.6 million, or 61 cents per share, from $822 million, or 76 cents per share, in the previous year. The results were dragged down 29 cents by the acquisitions of two companies, Hypnion Inc. and Ivy Animal Health Inc.

Excluding those charges, adjusted earnings totaled $978.7 million, or 90 cents per share. Analysts had expected 82 cents per share on that basis, according to Thomson Financial.

Lilly’s revenue topped forecasts as well, rising 20 percent to $4.63 billion. Analysts were expecting sales of $4.39 billion.

The jump was triggered in part by sales of the depression treatment Cymbalta, which surged 67 percent to $519.5 million. Lilly’s top-selling drug, the anti-psychotic Zyprexa, saw sales increase 9 percent to $1.2 billion.

“Sales were strong, so in terms of quality I think (the quarter) was very good,” said analyst Joseph Tooley of A.G. Edwards & Sons Inc.

Lilly raised its 2007 sales and profit guidance and is now forecasting full-year adjusted earnings per share in the range of $3.40 to $3.50, or $2.75 to $2.85 per share on a reported basis. On average, analysts were seeking profit of $3.39 per share.

Lilly shares closed unchanged at $57.17.

Revenue from another top Lilly product, the erectile tadalafil softtabs
drug Cialis, increased 26 percent to $293 million. Lilly now gets all the sales from that drug; previously it split the revenue with ICOS Corp., which it acquired this year.

The osteoporosis drug Evista saw slow growth, with sales rising 1 percent to $278 million. But it received a boost Tuesday when a U.S. Food and Drug Administration committee recommended its use to reduce the risk of invasive breast cancer for some women.

Cymbalta, Cialis and several other drugs launched this decade now comprise 32 percent of Lilly’s revenue total, reducing Lilly’s reliance on Zyprexa, which goes off patent in 2011.

“These products that they have launched are growing meaningfully … and they’re relatively early in their product life cycle,” Tooley said.

Company leaders also touted their product pipeline during a Tuesday conference call with analysts. President and Chief Operating Officer John Lechleiter said Lilly has had eight drugs enter early-stage clinical trial testing this year and expects to hit its goal of 15.

However, Miller Tabak and Co. analyst Les Funtleyder noted that drugs in early stages of development are too shaky to count on for future revenue.

“I still have some uncertainty about where the next couple of years worth of growth is going to come from,” he said. “I wish they had more in their late stage pipeline than they do.”

Fraud and underage consumers have always posed a problem when seeking online medications. It seems anyone can order medications online without verifying their age and their identity. Accessrx, an online pharmacy, makes it mandatory for each customer to be verified and validated before their order is processed.

Tempe, AZ (PRWEB) October 3, 2007 — Accessrx.com, the web's leading online pharmacy since 1999, has just introduced Secure Medical's innovative technology to process their orders. Once an order is placed online, the real work is done behind the scenes to ensure safety, security, and confidentiality.

For customers who are shopping online for their medications, these innovations also mean more than reduced fraud, protection against identity theft and lower priced impotence orgs. Accessrx.com provides assurance that only licensed American doctors and licensed American pharmacies are able to ship FDA approved medications. As a consumer, it is important to look for an online pharmacy that does not sell any controlled and/or generic pills. One example of a violation would be the sale of generic Viagra. The generic form of Viagra is in violation of U.S. patent law, including the Federal Food, Drug, and Cosmetic Act. The crackdown of online pharmacies that are illegally selling and importing non-FDA approved Viagra is something that Pfizer, the manufacturer of Viagra, monitors with great concern. Learn more about accessrx's erectile dysfunction product guarantee.

Each order placed by either phone, or web will receive a where to buy viagra on line
cross-check which verifies the customer's date of birth, address, zip code, and other relevant information.

“A cross-check is a real time verification process that can quickly verify a customer's age ,” says accessrx.com chief operating officer, Joel Korsunsky. “If Secure Medical concludes that the age does not match, we then request the customer to fax in their ID, or the order itself will be cancelled.”

Secure Medical is the online processing company that utilizes a real time verification service on e-script websites.

“So far in 2007, we have been able to identify and reduce incidents of fraud by 50% using this resource,” said C.O.O Joel Korsunsky.

Typically, a person using a stolen credit card gets caught in one of the many verification steps employed by Secure Medical. Another important advantage for the consumer is what your on line seller is doing to protect your personal information including credit card data. Secure Medical is PCI certified for maximum assurance in credit card storage information. Are you aware that over 155 Million records have been compromised in the United States, since February 2005?

In a recent survey conducted by accessrx.com which asked, “What convinced you to order with us (2,838 answers)?” The #1 reason for ordering was convenience, followed by security.

“When I want to buy Viagra online, I look for a website that has a telephone number, is located in the USA, ships FDA approved medications, and has a secure ordering process,” said Jim K., customer of accessrx.com.

These results were followed by other preferences such as privacy, product, price, and service. Customers appreciate the convenience and privacy of ordering genuine prescription medication, as an buy levitra vardenafil to going to their local pharmacy, which in the end, are factors higher rated than the concern about price itself.

About accessrx.com:
Accessrx is an online pharmacy where consumers can purchase; Viagra, cialis, levitra, chantix, propecia, and other leading lifestyle medications. They ship your prescription medication by Federal Express to ensure their customer's package is delivered accurately and on time. Their hydrochloride vardenafil customer care support team is available to handle calls 6:00 a.m. 7:30 p.m. M-SA.

Press Contact:
Rich Bernstein
Marketing Director
480-505-5725
www.accessrx.com

###

Secure Medical
Rich Bernstein
480-505-5725
E-mail Information

Trackback URL: http://prweb.com/pingpr.php/U3F1YS1TcXVhLUVtcHQtVGhpci1UaGlyLVplcm8=

The United States Government has approved the sale of a new drug expected to raise the stakes in the male impotence market.

Levitra, the first market rival to the hugely profitable Viagra, is being 5 citrate sildenafil tadalafil vs
by the German firm, Bayer AG, and marketed by the British firm GlaxoSmithKline (GSK) as an tadalafil cialis
oral therapy for erectile dysfunction.

Since its generic tadalafil
in 1998, sales of Pfizer’s Viagra have risen to nearly $2bn a year.

Both pills work in the same manner and doctors warn that both can have serious side effects, especially for men with heart problems.

A third tadalafil prezzo
pill, Cialis, is expected to reach the US market later this year.

The US Food and Drug Administration (FDA) approved Levitra, an orange pill compared to Viagra’s blue, based on studies showing that men were on average five times more likely to achieve an erection suitable for intercourse when taking the pill compared with those given a dummy medicine.

Researchers reported that studies of several thousand men showed that Viagra helped more than 70% improve their
erections.

As well as the warnings to men with heart liquid tadalafil
, the FDA said Levitra was not for patients with who had suffered a recent heart attack or stroke who have very low blood pressure or uncontrolled high blood pressure.

For otherwise healthy men, Levitra’s main side effects
were headache, flushing and a stuffy nose and sometimes dizziness.

Lawson Macartney, head of strategic management of GlaxoSmithKline’s cardiovascular, metabolic and urology drugs, said: “We know, from considerable market research, that the
market is ready for new options”.

GSK expects Levitra to be available in September.

A batch of a counterfeit obesity drug has been recalled by the UK’s medicines watchdog.

The Medicines and Healthcare Regulatory Agency (MHRA) said it was asking for the return of batch number 65542 of counterfeit Reductil 15mg.

The drugs were discovered within the UK supply chain, the second such discovery in recent days.

Last week, counterfeit Cialis capsules, used to treat erectile tadalafil cialis from india, were also discovered.

Prior to that, the last discovery of counterfeit drugs in the UK supply chain was in 1994.

However, the leading drug company Pfizer recently warned of the dangers of fake drugs entering the legitimate system.

It said this could happen because of “parallel packaging” - where drugs made in one country are repackaged for another.

Concerns

The MHRA said that initial tests on the fake Reductil tablets did not indicate that it posed an immediate risk to patients.

It advised anyone who had the product with the batch number 65542 anywhere on the pack should return it to where it was obtained.

Professor Kent Woods, chief executive of the MHRA, said: “Although the quality of counterfeit medicines cannot be guaranteed, there is no indication from testing
of the counterfeit product that it poses an immediate risk to patients.

“If patients have any concerns about possible side effects they should discuss them with their doctor.”

The MHRA said that no batches potenzmittel tadalafil
and distributed by Abbott Laboratories Ltd, the licence holder of the authentic Reductil tablets, were affected by this recall and there was no concern with the Abbott product.

David Pruce, Director of Practice and Quality Bulk citrate powder tadalafil
at the Royal Tadalafil guenstig
Society of Great Britain, said: “We know that counterfeit medicines are a world-wide problem but prior to the identification of these two products, counterfeiting in the UK had been a rare occurrence.

“The society has been working with the MHRA through our team of Inspectors and we ask pharmacists to co-operate with the MHRA’s drug tadalafil
and to be alert for counterfeit medicines.”

He added: “Patients are advised to contact their doctor or pharmacist in the event of any concern.”